Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by EMulate Therapeutics Inc

EMulate Therapeutics Announces Promotion of Kyle Kingma to SVP, Finance, and GM, EMulate Subsidiaries - Corporate Update Announcement
From EMulate Therapeutics Inc
Via AccessWire
Topics Initial Public Offering
Exposures Securities Market
EMulate Therapeutics Named 50 Leading Companies of the Year for 2022 by The Silicon Review
From EMulate Therapeutics Inc
Via AccessWire
Tickers TSX-V:HAPB
EMulate Therapeutics Announces Issuance Of 41st Patent Covering The Design Of A Pediatric Therapeutic Device For Cancer And Other Health Indications
From EMulate Therapeutics Inc
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
EMulate Therapeutics 2021 Year in Review - A Pivotal Year for the Company
From EMulate Therapeutics Inc
Via AccessWire
Tickers TSX-V:HAPB
EMulate Therapeutics Announces Poster Presentation of Its Confirmatory Pre-Clinical Pain Study Results at the 15th Annual Pain Therapeutic Summit at Washington, D.C. (Nov 1-3)
From EMulate Therapeutics Inc
Via AccessWire
EMulate Therapeutics Announces Positive, Confirmatory Pre-Clinical Data for its ulRFE(R) Technology Targeting Acute and Chronic Pain; Excellent Pain Reducing Effects Without the Use of Chemicals or Drugs
From EMulate Therapeutics Inc
Via AccessWire
EMulate Therapeutics Announces Positive Pre-Clinical Data in Mental Health Models and First in Human Experience Using its Proprietary Radio Frequency Energy Technology; Preliminary Results Emulate Drug Effects in Rodent Models and in Human Exposures
From EMulate Therapeutics Inc
Via AccessWire
EMulate Therapeutics Announces Issuance of Additional U.S. Patent Covering a Therapeutic Device for Cancer and Other Health Indications
From EMulate Therapeutics Inc
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
EMulate Therapeutics Announces Positive Pre-Clinical Data for its ulRFE(R) Technology Targeting Acute and Chronic Pain; Demonstrates Excellent Pain Reducing Effects Without the Use of Chemicals or Drugs
From EMulate Therapeutics Inc
Via AccessWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.